NAD vs NMN, NADH and NADP: what is the difference?

What is the difference between NAD and NAD+?

NAD is the general name for nicotinamide adenine dinucleotide, and NAD+ is its oxidised form, the form that can accept electrons. ChEBI lists NAD as a synonym of NAD+ (CHEBI:15846), so the two names usually point to the same molecule. Zhu et al. describe NAD as existing in the NAD+ or NADH form in all living cells (Proceedings of the National Academy of Sciences, 2015), which is why a reported NAD level can mean NAD+ alone or NAD+ plus NADH. A paper must say which one it measured.

The word supplement adds a second layer. In a 2024 systematic review of 10 randomised trials with 489 participants, the products studied were NADH and NAD+ precursors (Gindri et al., American Journal of Physiology-Endocrinology and Metabolism, 2024). A 2026 systematic review found no eligible outcomes trial of intravenous or intramuscular NAD+ for anti-ageing or wellness indications (Gallagher and Emmanuel, Ageing Research Reviews, 2026). In those two reviews, the supplements studied were NAD+ precursors or NADH, not NAD+ itself.

What is the difference between NAD+ and NADH?

NAD+ is the oxidised form and NADH the reduced form of the same coenzyme. ChEBI gives NAD+ as C21H28N7O14P2 with charge +1 and NADH as C21H29N7O14P2 with charge 0, a difference that fits NAD+ taking up one hydride, a hydrogen atom carrying an extra electron. In an observational study of 17 healthy volunteers aged 21 to 68, Zhu et al. measured both forms in living human brain and reported age-dependent falls in NAD+ and in the NAD+/NADH redox state, with NADH rising, an association that does not show a cause (Proceedings of the National Academy of Sciences, 2015). Redox state means the balance between the electron-poor and electron-rich forms.

In a cross-sectional comparison of 30 healthy adults aged 20 to 87, plasma NAD+ and NADP+ fell with age while the reduced forms NADH and NADPH rose, an association in one sample (Clement et al., Rejuvenation Research, 2019). Xiao et al. describe the NAD+/NADH pair as one of two redox couples that keep cells in redox balance (Antioxidants & Redox Signaling, 2018). Zhu et al. use the NAD+/NADH ratio, not only the total, as the measure of redox state (Proceedings of the National Academy of Sciences, 2015).

What is the difference between NAD+ and NADP+?

NADP+ is NAD+ with an extra phosphate group, and the two serve different parts of metabolism. ChEBI gives NADP+ as C21H29N7O17P3, which carries one more phosphorus atom and three more oxygen atoms than NAD+ (C21H28N7O14P2). Xiao et al. describe the NAD+/NADH and NADP+/NADPH pairs as two redox couples, each a pair of oxidised and reduced forms, with separate, compartmentalised pools inside cells (Antioxidants & Redox Signaling, 2018). ChEBI describes NADPH as used in anabolic reactions, such as lipid and nucleic acid synthesis (CHEBI:16474).

The two couples are not interchangeable. Xiao et al. state that the biosynthesis and distribution of NAD(H) and NADP(H) are highly compartmentalised, and that cells must keep both pools steady to avoid redox stress. In a cross-sectional sample of 30 healthy adults aged 20–87, plasma NADP+ and NAD+ were lower at older ages; this association does not establish causation (Clement et al., 2019).

Both couples matter in tissue studies. Thyroid tissue offers an example. In laboratory work on thyroid tissue from 13 patients (four with cold thyroid nodules and nine with diffuse toxic goiters), Cardoso et al. report findings that reinforce the hypothesis that an NADPH oxidase makes the hydrogen peroxide needed for thyroid hormone production, which is NADPH chemistry and not NAD+ chemistry, and which involves no NAD+ or precursor given to anyone (Journal of Clinical Endocrinology and Metabolism, 2001).

How do NAD+ and NMN differ, and which has stronger evidence?

NMN (nicotinamide mononucleotide) is a smaller molecule that cells convert into NAD+, so NMN is a precursor and NAD+ is the coenzyme itself. ChEBI gives NMN as C11H15N2O8P (CHEBI:16171), and Yoshino et al. describe NMN availability as a rate-limiting factor in mammalian NAD+ synthesis (Science, 2021). In an open-label randomised study of 65 healthy adults, 14 days of NMN raised circulating NAD+ about as much as nicotinamide riboside did while nicotinamide did not, and the study measured blood NAD+ and not health outcomes (Christen et al., Nature Metabolism, 2026). No study opened for this page ranks NAD+ itself against NMN on health outcomes.

NMN has human data of its own. In a 10-week placebo-controlled trial of 25 postmenopausal women with prediabetes who were overweight or obese, muscle insulin sensitivity rose after NMN and did not change after placebo, a small single-trial result for that group (Yoshino et al., Science, 2021). In a trial of 42 healthy men aged 65 or older randomised to NMN or placebo, with 20 completing 12 weeks, whole-blood NAD+ rose and body composition showed no significant effect, while the authors called nominally significant gait-speed and left-grip improvements findings to validate in larger studies (Igarashi et al., npj Aging, 2022). A 2024 meta-analysis of 8 randomised NMN trials in 342 middle-aged and older adults found no significant effect on glucose or lipid markers, within the limits of short trials and mostly non-diabetic participants (Chen et al., Current Diabetes Reports, 2024).

So which is better, NAD or NMN? This page reports no health-outcome ranking of the two from the sources it opened. In mice, an isotope-tracer study found that NMN given by one route was broken down to nicotinamide in the liver while NMN given by another route reached tissues intact, a mouse result that does not establish the same behaviour in people (Liu et al., Cell Metabolism, 2018). Evidence for NAD+ delivered directly is thinner, as the what NAD+ is page sets out.

Is NAD+ a coenzyme or a cofactor?

NAD+ is both, because a coenzyme is one kind of cofactor. ChEBI defines a cofactor as an organic molecule or ion, usually a metal ion, that an enzyme needs for its activity, attached either loosely (a coenzyme) or tightly (a prosthetic group) (CHEBI:23357). ChEBI defines a coenzyme as a low-molecular-weight, non-protein organic compound that acts as a dissociable acceptor or donor of chemical groups or electrons (CHEBI:23354), and lists both roles for NAD+. Covarrubias et al. call NAD+ a coenzyme for redox reactions and an essential cofactor for sirtuins, CD38 and PARPs (Nature Reviews Molecular Cell Biology, 2021).

In practice the words overlap. NAD+ moves electrons from one enzyme to another and then leaves, which is the loose attachment that makes it a coenzyme. FAD, by contrast, is listed in ChEBI as a prosthetic group, a cofactor that stays bound (CHEBI:16238).

What is the difference between NAD and NAC?

NAC is N-acetylcysteine, an acetylated form of the amino acid cysteine, and NAD+ is a dinucleotide coenzyme; the two share letters but not structure or role. ChEBI gives N-acetyl-L-cysteine as C5H9NO3S (CHEBI:28939) and NAD+ as C21H28N7O14P2. Tenório et al. describe NAC as a medicine widely used for paracetamol overdose and as a mucolytic, with an antioxidant role that comes from raising intracellular glutathione (Antioxidants, 2021). NAD+ has two sugar-phosphate units, adenine and a nicotinamide ring; it transfers electrons in redox reactions and is consumed by other enzymes, including sirtuins, PARPs and CD38 (Covarrubias et al., 2021).

Neither molecule stands in for the other. NAC is a medicine in its own right and has its own safety record, and NAD+ research material is not NAC and is not a substitute for any medicine. Searches that mix the two names usually reflect a spelling accident, not a shared pathway.

How do NAD+ and CoQ10 differ, and is one better?

CoQ10 (coenzyme Q10) is a different molecule from NAD+, and no study opened for this page compares them head to head, so this page reports no head-to-head ranking from the sources it opened. ChEBI gives CoQ10 as C59H90O4, a ubiquinone with a side chain of 10 isoprenoid units (CHEBI:46245), and NAD+ as C21H28N7O14P2. Hernández-Camacho et al. describe coenzyme Q as an essential part of the mitochondrial electron transport chain and an antioxidant in plasma membranes, made in all cells (Frontiers in Physiology, 2018). NAD+ is a coenzyme for redox reactions in energy metabolism (Covarrubias et al., 2021).

Both work in the cell’s energy machinery, which is why they are often named together. Their jobs differ: NAD+ carries electrons between many enzymes and is consumed by others, while coenzyme Q sits in the membrane chain that passes electrons on. “Better” has no meaning without an outcome, and the trials of each molecule measured different outcomes in different groups.

What does research show NAD+ does in the body, and what do NAD+ supplement trials measure?

In cells, NAD+ carries electrons in energy metabolism and is consumed by sirtuins, PARPs and CD38, enzymes linked to DNA repair, chromatin remodelling, cellular senescence and immune cell function (Covarrubias et al., Nature Reviews Molecular Cell Biology, 2021). Trials of NAD+ precursors mostly measure blood NAD+ and related metabolites, then outcomes such as insulin sensitivity, muscle function and blood pressure, in small groups over weeks (Yoshino et al., 2021; Igarashi et al., 2022; Martens et al., Nature Communications, 2018). A 2026 systematic review of 33 human intervention studies found consistent changes in NAD-related metabolites but mixed, often null, functional effects, across differing products, populations and duration, with clinical effectiveness inconclusive (Gallagher and Emmanuel, Ageing Research Reviews, 2026).

That separates two claims: NAD+ matters in cell chemistry, and raising blood NAD+ changes a health result. The first rests on the enzyme biology that Covarrubias et al. review (Nature Reviews Molecular Cell Biology, 2021). The second is what the trials test: in a 2026 systematic review of 33 human intervention studies with differing interventions, populations and duration, Gallagher and Emmanuel found the answers mixed and judged clinical effectiveness for anti-aging or wellness outcomes inconclusive (Ageing Research Reviews, 2026). NAD+ is not a peptide, so the phrase “NAD peptides” is a naming slip; the NAD+ peptide check shows why.

The question of what NAD+ is studied for belongs to trial design. Studies enrolled specific groups, such as overweight women with prediabetes, older men and obese men, and a result in one group does not transfer to another. The NAD+ research guide and the catalogue entry for NAD+ reference material describe the laboratory material, which is not a medicine.

What does NAD stand for in medicine, nursing and doctors’ notes?

In doctors’ notes, nursing charts and medical records, NAD abbreviates “nothing abnormal discovered” or “no abnormality detected”, not the molecule NAD+. The NHS App help list gives nothing abnormal discovered (page reviewed 24 March 2026). The Sydney Children’s Hospitals Network lists No Abnormality Detected (policy 2016-9005, version 3.2, effective 1 May 2024), and the Queensland Health Primary Clinical Care Manual list, 12th edition, 2025, gives No abnormalities detected. Each entry records a finding: an examiner saw nothing out of the ordinary.

Context separates the meanings. A chart line such as an examination followed by NAD is a finding, while NAD+ in a biochemistry paper is a molecule. The NHS App page warns that the same abbreviation can mean different things to different clinicians, and the Sydney policy states that only approved abbreviations may be used in medical records. The what NAD+ is page covers the abbreviation in full.

Is NAD+ similar to Ozempic?

No. NAD+ is a coenzyme found in all cells, while Ozempic’s active ingredient, semaglutide, is a modified version of the hormone GLP-1 that binds the GLP-1 receptor. The U.S. prescribing information for Ozempic (DailyMed label, updated 1 June 2026, prescribing information revised 5/2026) describes semaglutide as a GLP-1 analogue with 94% sequence homology to human GLP-1 that acts as a GLP-1 receptor agonist. ChEBI describes NAD+ as a coenzyme that carries electrons in metabolism. The label adds that the peptide backbone of semaglutide is produced by yeast fermentation.

Ozempic is an approved prescription medicine with a U.S. prescribing label, and research material is not a substitute for it or for any medicine. The label describes semaglutide as a GLP-1 receptor agonist and ChEBI describes NAD+ as an electron-carrying coenzyme, and the two have different trial records. No trial opened for this page compares NAD+ or its precursors with semaglutide.